June 2015

Vedolizumab (Entyvio) is recommended by NICE as a possible treatment for adults with moderate to severe ulcerative colitis.

People should be able to have the treatment until it stops working or surgery is needed. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have it. If they no longer have symptoms, treatment could be stopped, and later restarted if symptoms return.

People who continue to take vedolizumab should be assessed at least every 12 months to see whether the treatment is working well enough for them to carry on taking it.